Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
IFIS JAPAN, 14% Increase in Ordinary Profit for The Current Fiscal Year, Dividend Raised by 2 yen
7833 IFIS JAPAN LTD. 【J-GAAP】
Earnings ReportIFIS JAPAN LTD. <7833> [TSE Std] announced its financial results after the market closed on February 13th (15:30). The consolidated ordinary profit for the fiscal year ending December 2024 decreased 3.6% from the previous period to 678 million yen. In the fiscal year ending December 2025, the profit is expected to expand to 13.6% to 770 million yen. This will be the fourth consecutive term of revenue growth.
At the same time, the company has decided to increase the dividend this fiscal year to 21.5 yen, an increase of 2 yen from the previous fiscal year.
In the most recent three-month period, from October to December (4Q), the consolidated ordinary profit dropped to 125 million yen, a 32.4% decrease compared to the same period last year. The operating profit margin significantly dropped from 13.4% in the same period last year to 7.2%.
Kabutan News
Actual Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Dec, 2022 | 5,380 | 826 | 834 | 587 | 60.8 | 18.50 | Feb 10, 2023 | J-GAAP |
Dec, 2023 | 5,554 | 698 | 703 | 448 | 46.5 | 18.50 | Feb 13, 2024 | J-GAAP |
Dec, 2024 | 5,859 | 677 | 678 | 422 | 43.8 | 19.50 | Feb 13, 2025 | J-GAAP |
YoY | +5.5% | -3.0% | -3.6% | -5.8% | -5.8% |
Full Year Results vs. Previous Guidance
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Dec, 2024 Guidance | 5,700 | 720 | 720 | 465 | 48.3 | 19.50 | Feb 13, 2024 | J-GAAP |
Dec, 2024 Results | 5,859 | 677 | 678 | 422 | 43.8 | 19.50 | Feb 13, 2025 | J-GAAP |
Revision Rate | +2.8% | -6.0% | -5.8% | -9.2% | -9.2% |
Current Period Guidance
H1 Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Jan - Jun, 2024 | 2,771 | 372 | 374 | 248 | 25.8 | 0 | Aug 9, 2024 | J-GAAP |
Jan - Jun, 2025 Guidance | 3,500 | 350 | 350 | 231 | 24.0 | 0 | Feb 13, 2025 | J-GAAP |
YoY | +26.3% | -5.9% | -6.4% | -6.9% | -6.9% |
Current Period Guidance
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Dec, 2023 | 5,554 | 698 | 703 | 448 | 46.5 | 18.50 | Feb 13, 2024 | J-GAAP |
Dec, 2024 | 5,859 | 677 | 678 | 422 | 43.8 | 19.50 | Feb 13, 2025 | J-GAAP |
Dec, 2025 Guidance | 7,150 | 770 | 770 | 510 | 52.9 | 21.50 | Feb 13, 2025 | J-GAAP |
YoY | +22.0% | +13.7% | +13.6% | +20.9% | +20.8% |
Quarterly Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Oct - Dec, 2023 | 1,376 | 185 | 185 | 121 | 12.6 | 13.4 | Feb 13, 2024 | J-GAAP |
Jan - Mar, 2024 | 1,406 | 195 | 196 | 131 | 13.6 | 13.9 | May 13, 2024 | J-GAAP |
Apr - Jun, 2024 | 1,365 | 177 | 178 | 117 | 12.2 | 13.0 | Aug 9, 2024 | J-GAAP |
Jul - Sep, 2024 | 1,372 | 181 | 179 | 120 | 12.5 | 13.2 | Nov 13, 2024 | J-GAAP |
Oct - Dec, 2024 | 1,716 | 124 | 125 | 54 | 5.6 | 7.2 | Feb 13, 2025 | J-GAAP |
YoY | +24.7% | -33.0% | -32.4% | -55.4% | -55.4% |
Related Articles
Kumagai Gumi, The Current Fiscal Year Ordinary Profit Revised Downward to an Unexpected 8% Decrease
CREATE MEDIC, 39% Increase in Ordinary Profit for The Current Fiscal Year
Disruptors, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 5.6 times, Oct-Dec Ordinary Profit Turns to Profit
TAIKO PHARMA, 71% Decrease in Ordinary Profit for The Current Fiscal Year
Vertex, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 9%
Nippon Soda, Oct-Dec (3Q) Ordinary Profit Increases by 3%
EBRAINS, Apr-Dec (Cumulative 3Q) Ordinary Profit Decreases by 16%
GOURMET KINEYA, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 2.4 times, Exceeds Full-Year Plan
LAND BUSINESS, Oct-Dec (1Q) Net Income Turns to Loss
Mitsubishi Materials, The Current Fiscal Year Ordinary Profit Revised Downward by 6%